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Objective. To investigate HRPT2 in jaw ossifying fibroma (OF), fibrous dysplasia (FD), and osteosarcoma (OS).
Study Design. We combined microsatellite loss of heterozygosity (LOH), HRPT2 sequence alterations at the mRNA level by
reverse-transcription polymerase chain reaction (PCR), cDNA sequencing, and quantitative PCR (qPCR) and
immunohistochemistry (IHC) in a total of 19 OF, 15 FD, and 9 OS. Because HRPT2 (parafibromin) interacts with cyclin D1,
we investigated cyclin D1 expression with the use of qPCR and IHC.
Results. LOH was detected in 3/5 FD, 6/9 OF, and 2/2 OS heterozygous samples. LOH was not associated with decreased
mRNA levels or HRPT2 protein expression except for 1 OF which harbored an inactivating mutation. However, this tumor
did not display altered transcription or protein levels of HRPT2 nor cyclin compared with the other OF.
Conclusions. The contribution of HRPT2 inactivation to the pathogenesis of OF, FD, and OS is marginal at best and may be
limited to progression rather than tumor initiation. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:359-367)Fibrous dysplasia (FD) and ossifying fibroma (OF) are
benign fibro-osseous lesions that can affect the maxil-
lofacial bones1-3 and are characterized by bone replace-
ment with cellular fibrous tissue containing foci of
mineralization that vary in amount and appearance.4
The molecular mechanisms involved in the patho-
genesis of these benign lesions are for the most part
unknown. FD has been associated with somatic postzy-
gotic activating mutations in the GNAS1 gene,5,6 sup-
porting earlier studies that suggested that FD is a mono-
clonal lesion.7,8 However, most clonality studies were
based on X chromosome inactivation assays, which for
the most part did not consider tumor heterogeneity and
the existence of several subclones in the tumor tis-
sue.9,10 Indeed, the GNAS-activating mutation has been
shown to exist in a mosaic pattern in anatomically
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http://dx.doi.org/10.1016/j.oooo.2012.11.015distinct regions of the same tumor, a finding that further
supports oligoclonality of this tumor type.11,12 Unlike
FD, clonality of OF has never been reported in peer-
reviewed journals.
OS is a malignant bone tumor, rare in the head and
neck regions, whose exact underlying molecular mech-
anisms remain elusive. Somatic genetic alterations have
been reported in this tumor type, and notably, germline
mutations in the Rb and P53 genes are associated with
an increased lifetime risk for developing this tu-
mor.13,14
The HRPT2 tumor suppressor gene localizes to
1q24-32 and encodes for a 531–amino acid–long pro-
tein, called parafibromin, that exerts some of its anti-
proliferative activities via interaction with cyclin
D1.15,16 Germline mutations and somatic inactivation
of HRPT2 are associated with hyperparathyroidism–
jaw tumor syndrome (HPT-JT; OMIM #145001), a
tumor predisposition syndrome characterized by para-
thyroid tumors, benign fibro-osseous lesions (BFOL) of
the mandible and maxilla, renal cysts, and Wilms tu-
mor.15-21 Our group previously described germline and
somatic mutations of HRPT2 in 2/3 OF.22 Given some
similarities in histologic features and anatomic loca-
tion, we hypothesized that HRPT2 may also be in-
Statement of Clinical Relevance
Loss of heterozygosity at the HRPT2 gene locus is
found in ossifying fibromas, fibrous dysplasias, and
osteosarcomas. However, this gene seems to be
mutated only in ossifying fibromas.359
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sions—FD and osteosarcoma (OS). In addition, we
aimed at defining the extent that this gene is involved in
seemingly sporadic OF.
MATERIALS AND METHODS
Tumors analyzed—identification and recruitment
A total of 15 FD, 19 OF, and 9 OS samples was
evaluated in the study, including 6 FD, 10 OF, and 2
OS fresh human tumor samples. Seven normal bone
samples from third molar extractions with no clinical
evidence of inflammation or neoplasm were also col-
lected. The study was approved by the Ethics Commit-
tee of the Universidade Federal de Minas Gerais, and
each of the participants gave informed consent. Four
OF cases had already been included in a previous
study.22 In addition to the freshly collected and ana-
lyzed lesions, 9 FD and 9 OF were also selected from
the files of the Oral Pathology Service of Universidade
Federal de Minas Gerais and 7 OS from the files of the
Pathology Division, Centro Clinico de Cabeza y
Cuello/Hospital Herrera-Llerandi, Guatemala, to be in-
cluded in the immunohistochemistry analyses. These
Table I. Demographic data of the fresh samples inclu
Sample Sex Age, y Location
Fibrous dysplasia
Case 1 Female 56 Maxilla
Case 2 Female 24 Mandible
Case 3 Male 14 Maxilla
Case 4 Female 14 Mandible
Case 5 Female 30 Maxilla
Case 6 Female 28 Maxilla
Ossifying fibroma
Case 7 Female 30 Mandible
Case 8a Female 33 Mandible
Case 9 Female 57 Mandible
Case 10b Male 19 Mandible
Case 11c Male 17 Mandible
Case 12 Female 25 Mandible
Case 13 Female 28 Maxilla
Case 14 Female 30 Maxilla
Case 15 Female 49 Maxilla
Case 16 Female 70 Mandible
Osteosarcoma
Case 17 Female 34 Mandible
Case 18 Female 35 Mandible
Case 19 Female 15 Maxilla
Case 20 Male 21 Mandible
Cases 7, 9, 10, and 11 were previously reported.22 Cases 19 and 20 w
cases, 9 FD, 9 OF, and 5 OS FFPE samples were included in the IHC
reverse-transcription polymerase chain reaction; qPCR, quantitative
aCase 8  recurrence of case 7.
bJuvenile ossifying fibroma.
cHyperparathyroidism–jaw tumor syndrome.paraffin-embedded samples were obtained after in-formed consent and with the approval of the local
Ethics Committees.
Tumor and control tissue processing
A portion of each fresh lesion and control sample was
stored in RNA Holder (Bioagency Biotecnologia, São
Paulo, SP, Brazil) at 80°C, and another part was stored
in 10% buffered formalin and paraffin embedded for he-
matoxylin and eosin (HE) staining and immunohisto-
chemistry (IHC). The precise diagnosis of each tumor
type was based on clinical, radiographic, surgical, and
histologic features as described elsewhere.4,23,24 All OF
were conventional, except 1 case that was a juvenile OF
and 1 case that was associated with HPT-JT. These 2
nonconventional OF are listed in Table I.
DNA isolation and microsatellite analysis
HE staining was performed to establish the presence of
tumorous and nontumorous tissue. Five samples of FD,
9 OF, and 4 OS underwent microsatellite analysis.
Tissue was microdissected from a series of 20-m-
thick paraffin-embedded tissue sections under direct
viewing, with the use of a stereoscopic microscope and
d experiments carried out with each of them
Assay
LOH IHC RT-PCR and sequencing qPCR
X X X X
— — X X
X X X X
X X — X
X X — X
X X — X
X X X X
X X X X
X X X X
X X X X
X X X X
— X X X
X X X X
X X X X
X X — X
X — — —
X X X X
X X X X
X X — —
X X — —
malin-fixed paraffin-embedded (FFPE) samples. In addition to these
LOH, loss of heterozygosity; IHC, immunohistochemistry; RT-PCR,
R; X, performed; —, not possible to analyze.ded an
ere for
assay.
RT-PCsurgical blade. Microdissected tissues fragments were
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extracted with the use of the DNeasy Blood and Tissue
Kit (Qiagen, Hilden, Germany). DNA was amplified
with -globin as an internal control.
Loss of heterozygosity (LOH) was assessed with
the use of 2 polymorphic DNA markers located in the
long arm of chromosome 1, D1S384 (1q25.3) and
D1S461 (1q25.3), flanking HRPT2. Marker positions
and their relation to the HRPT2 locus are illustrated
in Figure 1. Fluorescent-labeled primers and PCR
conditions were used as previously described.25 Am-
plification products were detected with the use of an
ABI Prism 310 (Applied Biosystems, Foster City,
CA, USA), and data were analyzed with the use of
Genemapper software version 3.0 (Applied Biosys-
tems,). Normal microdissected tissue was first eval-
uated for informative status (i.e., heterozygosity) for
Fig. 1. Ideogram with the cytogenetic bands of chromosome
1. Polymorphic DNA markers located on the long arm of
chromosome 1, including D1S384 (1q.25.3) and D1S461
(1q25.3), were used to assess loss of heterozygosity at the
HRPT2 genetic locus.each marker. Homozygous normal tissue markerswere considered to be noninformative. Alleles were
assessed as being in balance when the ratio of the
individual allele peaks fell within the range of 0.66
or 1.50.26 LOH was calculated as previously de-
scribed by van Houten et al. (2000).27
Parafibromin and cyclin D1
immunohistochemistry
Tissue sections from 14 FD, 18 OF, and 9 OS were
immunostained with parafibromin and cyclin D1 anti-
bodies. Parafibromin expression was evaluated with the
use of a murine monoclonal antibody that targets the
peptide corresponding to amino acid 87-100, encoded
by exon 3 of HRPT2 (sc-33638; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA).28 Briefly, deparaf-
finized 4-m sections were steamed in citrate buffer
(pH 6) for 30 minutes. Then, endogenous peroxidase
activity was blocked with 10% H2O2 in methanol for 10
minutes. The parafibromin antibody was diluted at
1:200 and the cyclin D1 (clone DCS-6; Dako, Golstrup,
Denmark) at 1:100 and incubated for 30 minutes at
room temperature. Sections were incubated in Envision
 Dual Link System–horseradish peroxidase (Dako,
Carpinteria, CA, USA) for 30 minutes at room temper-
ature, and reactions were revealed with 3,3=-diamino-
benzidine (Sigma, St. Louis, MO, USA) with timed
monitoring using a positive control sample (oral squa-
mous cell carcinoma with known reactivity). The sec-
tions were then counterstained with Mayer hematoxy-
lin. Sections in which the primary antibody was omitted
served as negative control.
Six digital images of each case were captured with a
digital micro camera (JVC TK-1270/RGB; Tokyo, Ja-
pan) at400 magnification interfaced with a computer.
Total and positive-staining cells were identified within
the digitalized images by means of the software Image
Tool 3.0 (University of Texas Health Science Center,
San Antonio, TX, USA). Both parafibromin and cyclin
D1 staining were evaluated in the nucleus regardless of
staining intensity.22 Indexes of labeled cells for parafi-
bromin and cyclin D1 were obtained by dividing the
positive cells by the total number of tumor cells and
multiplying by 100.
RNA extraction, complementary DNA synthesis,
and mutational screening of the HRPT2 transcript
Total RNA was extracted from 6 FD, 9 OF, and 2 OS
freshly obtained samples, as well as from 7 normal
jaw bone samples, applying Trizol reagent according
to the manufacturer’s recommended protocol (Invit-
rogen, Carlsbad, CA, USA). Total RNA was treated
with DNase, and the reverse transcription of 1 g
RNA to complementary DNA (cDNA) was per-
formed with the use of Superscript III First-Strand
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tions.
The transcript sequence of HRPT2 was amplified and
sequenced from the tumor cDNA obtained from patients
with FD (n  3), OF (n  8), and OS (n  2) (Table I).
cDNA was used as a template for the PCR amplification
of the full-length transcript of the human HRPT2 cDNA,
using primers previously described.29 The GenBank ac-
cession number NM_024529.3 was used as a reference
sequence (nucleotide  1 corresponds to the A of the
ATG-translation initiation codon). -Actin cDNA was
amplified as an internal control. The amplified products
were electrophoresed on a 1.5% agarose gel, purified with
the use of the GFX PCR DNA and Gel Band Purification
Kit (Amersham Biosciences, Piscataway, NJ, USA), and
sequenced on the ABI Prism 310 Genetic Analyzer (Ap-
plied Biosystems).
Quantitative reverse-transcription PCR
For quantitative PCR (qPCR) analyses, wild-type tran-
scripts of the HRPT2 and Cyclin D1 cDNA were de-
tected with 1 Sybr Green PCR Master Mix (Applied
Table II. Results of real-time PCR, immunohistochem
Sample
Cyclin D1 gene
qPCR (RQ) % IHC positivity
Fibrous dysplasia
Case 1 7.246 0
Case 2 9.881 —
Case 3 6.223 88
Case 4 — 0
Case 5 36.594 0
Case 6 12.351 33.5
Ossifying fibroma
Case 7 47.954 0
Case 8a 102.882 0
Case 9 12.001 0
Case 10b 10.632 0
Case 11c 91.392 0
Case 12 10.794 0.6
Case 13 3.905 0.4
Case 14 11.890 0
Case 15 23.729 0
Case 16 — —
Osteosarcoma
Case 17 15.640 0
Case 18 4.973 0
Case 19 — 0
Case 20 — 0
Cases 7, 9, 10, and 11 were previously reported.22 We could not ext
loss of heterozygosity (LOH) analyses. Case 16 was included only
tochemistry (IHC) and LOH analyses. qPCR results are represented
abbreviations as in Table I.
aCase 8  recurrence of case 7.
bJuvenile ossifying fibroma.
cHyperparathyroidism–jaw tumor syndrome.Biosystems, Warrington, UK). Samples included in theqPCR assay are listed in Table I. Reaction conditions
were as previously described.30 HRPT2 and Cyclin D1
primers were designed with the use of the Primer Ex-
press software (Applied Biosystems, Foster City, CA,
USA), version 3.0, yielding PCR products of 116 bp
(Cyclin D1) and 126 bp (HRPT2). The primer se-
quences were HRPT2 F5=GCCAACCCAGAGAGT-
ACTACACATT3= and R5=GATCAGGTCTTCTAAC-
CACAGGAATAT3= and Cyclin D1 F5=TGAGGA-
GCCCCAACAACTT3= and R5=CAGCAGGGCTTC-
GATCTG3=. Data were presented as the relative quan-
tity of a target gene normalized to endogenous -actin
and relative to a calibrator sample (reference), i.e.,
relative quantification (RQ). Relative quantification of
these genes expressions was calculated with the 2		Ct
method. As a calibrator, a pool of normal mucosa
samples was included. As controls, normal bone sam-
ples were included (from a total of 7, only 2 resulted in
good quality RNA extraction and cDNA synthesis).
Statistical analysis
Mann-Whitney, Spearman correlation, and Fisher exact
s well as LOH analyses in fresh samples
HRPT2 gene
Microsatellite marker at
1q25.3
CR (RQ) % IHC positivity D1S384 D1S461
0.706 85.73 LOH hom
3.085 — — —
0.324 100 het hom
3.304 100 het hom
0 99 het LOH
1.113 100 het LOH
7.366 98.43 het het
4.503 65.67 LOH LOH
2.281 85.73 hom het
0.372 100 hom LOH
2.627 98.81 LOH het
2.428 94.20 — —
2.384 97.70 het LOH
1.198 96.50 hom LOH
7.056 100 het LOH
— — het het
4.912 89.56 hom LOH
0 100 LOH hom
— 93 hom hom
— 86.50 hom hom
mal DNA from cases 2 and 12 and so they were not included in the
OH assay. Cases 19 and 20 were included only in the immunohis-
relative quantification). het, heterozygous; hom, homozygous; otherical, a
qP
ract nor
in the L
in RQ (tests were used. All statistical analyses were carried out
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probability values of .05 were considered to be sta-
tistically significant.
RESULTS
The results of molecular analyses (LOH, IHC, mRNA
transcription, and sequencing) and the main clinical
characteristics of all fresh sample lesions are presented
in Tables I and II.
Five samples of FD, 9 OF, and 4 OS samples then
underwent microsatellite analyses (Table I). Eleven in-
formative samples, (i.e., heterzygous) exhibited LOH at
the HRPT2 locus: 3/5 FD samples, 6/9 OF samples, and
2/2 OS cases (Table II). Representative results of LOH
in the region 1q25.3 at the HRPT2 gene locus are
depicted in Figure 2.
The overall IHC results are displayed in Figure 3,
and the immunostaining pattern of parafibromin and
cyclin D1 are shown in Figure 4. Parafibromin and
cyclin D1 staining were identified almost exclusively in
the nucleus. Although all of the 41 lesions evaluated
showed strong parafibromin positivity, only 9 of them
showed cyclin D1 positivity (including 3 OF, 4 FD, and
2 OS). Although OF lesions expressed more parafibro-
min protein than OS (P  .05; Mann-Whitney test), no
statistically significant differences could be observed
among the 3 groups of lesions in cyclin D1 immuno-
expression (P  .05; Mann-Whitney test). No correla-
tion was noted between parafibromin and cyclin D1
protein immunostaining (P  .05; Spearman correla-
tion test).
Direct sequencing of all coding regions of the
Fig. 2. Representative results of HRPT2 loss of heterozygo
showed LOH is represented (score0.66 or1.50). Tumor D
B, D1S461) compared with normal DNA. *Alleles.HRPT2 gene at the cDNA level was performed in 3 FD,8 OF, and 2 OS fresh tumor samples (Table I). Only 1
OF harbored an inactivating mutation in exon 1
(c.70delG), which predicts a premature truncation of
parafibromin at codon 25 (Figure 5). This mutation was
detected in both primary (case 7) and recurrent samples
(case 8). DNA of this same primary tumor was previ-
ously sequenced and demonstrated the same mutation,
which was not detected in germline DNA.22 This pri-
mary sample also revealed a large deletion (from codon
OH). The recurrent ossifying fibroma sample (case 8) that
id not retain the long allele for both markers (A, D1S384; and
Fig. 3. Percentage of immunopositive cells for cyclin D1
(solid circles) and parafibromin (open circles) of all lesions.
Total samples per group: fibrous dysplasia (FD), 14; ossifying
fibroma (OF), 18; and osteosarcoma (OS), 9.sity (L
NA d415 to codon 440) in transcript encoded by exons 14-15
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CTTATAGAGTAGTAGACCAGCCCCTTAAACTT-
ATGCCTCAAGACTGGGA that could not be detected
in the sample of the recurrent tumor. We did not find
mutations in the HPT-JT OF sample (case 11) that had
previously shown a heterozygous germline DNA mu-
tation,22 even after repeated sequencing and PCR with
2 distinct tumor portions.
Results of relative quantification of HRPT2 and Cyclin
D1 mRNAs are presented in Table I and displayed in
Figure 6. The 2 normal bone fragments expressed -actin
but did not express either HRPT2 or cyclin D1 transcripts.
Fig. 4. Immunostaining pattern of parafibromin and cyclin
exclusively nuclear. A, B, FD; C, D, OF; E, F, OS. A, C, E,
Original magnification 400. Abbreviations as in Figure 3.All samples expressed more cyclin D1 than did the normalmucosa. One FD (case 5) and 1 OS (case 18) did not show
HRPT2 mRNA transcription. The transcriptional levels of
Cyclin D1 and HRPT2 were similar in the 3 groups of
lesions. (P  .05; Mann-Whitney test.)
Overall, HRPT2 mRNA expression was not different
in the group of lesions displaying HRPT2-linked
marker LOH compared with the group of lesions that
exhibited no allelic loss at the HRPT2 locus. The 2
samples that did not express HRPT2 mRNA [cases 5
(FD) and 18 (OS)], both had evidence of LOH albeit
with different markers. Yet in both these lesions, almost
100% of the tumor cells expressed parafibromin as
Note that immunostaining of both antibodies was almost
romin immunostaining; B, D, F, cyclin D1 immunostaining.D1.
Parafibassessed by IHC.
RPT2
s 7-15
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HRPT2 mRNA (expressed less than the calibrator)
were cases 1 and 3 (FD) and 10 (juvenile OF). Cases 1
and 10 showed LOH at the HRPT2 locus, whereas case
3 did not. All 3 samples showed positive parafibromin
immunostaining for 85%-100% and showed no se-
quence alteration of the HRPT2 cDNA.
The sample representing an OF recurrence (case 8)
revealed LOH using both markers, whereas the primary
lesion (case 7) did not show LOH. The recurrent lesion
Fig. 5. Mutation in the mRNA transcript of the recurrent ossif
transcript of the primary and recurrent OF samples (case 7 a
predicts a premature truncation of parafibromin at codon 25 in
primary and recurrent OF samples (case 7 and 8) showing H
Fig. 6. Transcriptional levels of HRPT2 and Cyclin D1
polymerase chain reaction in the samples of the 3 groups. Tw
the calibrator; 1 FD (case 5) and 1 OS (case 18) did not expr
than did the calibrator. The 2 normal bone fragments includ
express HRPT2 and Cyclin D1 mRNAs. Cases 1-6: FD; caseshowed decreased transcriptional levels and immuno-expression of HRPT2/parafibromin in addition to in-
creased Cyclin D1 transcription compared with the
primary lesion of the same patient.
DISCUSSION
The present study assessing the involvement of the
HRPT2 gene in the pathogenesis of 3 bone lesions in
the maxillomandibular region, shows that despite the
frequent allelic loss at the HRPT2 locus in these le-
sions, this finding did not correlate with either somatic
broma (OF) case. A, Sequence analysis of the HRPT2 mRNA
revealed a G deletion involving codon 24 (c.70delG), which
1 (p.Glu25X). B, Eletropherogram (sequencing results) of the
exon 1 c.70delG. Arrow shows the G deletion point.
s analyzed by quantitative real-time reverse-transcription
case 1 and 3) and 1 OF (case 10) expressed less HRPT2 than
PT2. The other cases expressed more HRPT2 and Cyclin D1
this study expressed only the endogenous gene and did not
: OF; and cases 17-18: OS; abbreviations as in Figure 3.ying fi
nd 8)
exonmRNA
o FD (
ess HR
ed inmutations or a discernible effect on mRNA or protein
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lyzed. One plausible but speculative explanation is that
the allelic loss detected herein targets another tumor
suppressor gene that resides within the same chromo-
somal region. Interestingly, there are other tumor sup-
pressor candidate genes located at the same genetic
locus, 1q25, such as RNASEL, which are involved in
regulation of cell proliferation and apoptosis.31 Another
candidate to be targeted by the LOH is GLRX2, which
was previously associated with cellular differentiation
and transformation, possibly with a role in tumor pro-
gression in lung cancer32 and in melanoma cell lines.33
Moreover, a previous publication showed a germline
mutation in an HPT-JT family affecting the whole
HRPT2 gene and including other genes closely related
to HRPT2, such as TROVE2 and GLRX2.34 Therefore,
we can speculate that these genes are also possible
targets of LOH.
In the present study, even when somatic inactivating
mutations in the HRPT2 gene were found in the pri-
mary and recurrent tumors from a single individual, and
1 of the 2 tumors also showed allelic loss, these lesions
expressed normal parafibromin protein as assessed by
IHC. This may be the result of tumor heterogeneity,
where different clones exist in the same tumor: In some
clones, HRPT2 is inactivated, and in others HRPT2
expression is maintained because these clones lack the
inactivating mutation. It may also indicate that HRPT2
inactivation is not an early event that drives the initia-
tion of tumorigenesis in this tumor type but is rather a
progression-promoting event. However, firm conclu-
sions can not be drawn based on this single case.
In cell culture models, parafibromin showed antiprolif-
erative properties and the ability to inhibit cyclin D1
expression,16,35 suggesting an obvious model for neopla-
sia resulting from the loss of the parafibromin function.
An interesting finding was that the recurrent OF showed
decreased transcriptional levels and immunoexpression of
HRPT2/parafibromin in addition to increased Cyclin D1
transcription compared with its primary counterpart. This
recurrent lesion presented LOH at the HRPT2 locus.
However, such a clear relation between HRPT2 and cyclin
D1 expression could not be drawn for the other lesions.
Therefore, it is not clear if cyclin D1 regulation results
from a direct or indirect action of parafibromin in the
subset of bone lesions included in our study. Further work
on parafibromin and cyclin D1 and their integration with
other regulatory pathways will clarify their precise role in
transcriptional regulation and the pathogenesis of these
bone lesions.
There is a paucity of data published on the molecular
mechanisms underlying these jaw bone lesions. Nota-
bly, 1 case of OF has been published that described
somatic mutation of the HRPT2 gene (same case in-cluded in this study) and a second case presented a
germline mutation.22 Therefore, from the currently
available data, we can conclude that the contribution of
HRPT2 gene inactivation to the pathogenesis of OF,
FD, and OS is marginal at best and may be limited to
the progression of the tumor rather than its initiation.
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